Impurity Characterization of GLP-1 Receptor Agonists via RPLC and HILIC
Glucagon-like peptide-1 (GLP-1) receptor agonists—including Semaglutide, Exenatide, and Tirzepatide—are synthetic peptide therapeutics widely used in the management of type 2 diabetes and obesity. Due to their structural complexity and susceptibility to degradation and related impurities, robust analytical methods are essential for quality control and regulatory compliance.
This presentation highlights two orthogonal chromatographic approaches for impurity profiling: reversed-phase liquid chromatography (RPLC) and hydrophilic interaction chromatography (HILIC). We will discuss method development strategies to optimize separation performance, including considerations for gradient design, column chemistry, temperature control, and mobile phase composition. These insights aim to support analysts in achieving high-resolution separations and reliable impurity characterization of GLP-1 analogs.
Presenter: Andrea Ngai (BioPharma Technical Specialist, Agilent Technologies, Inc.)
Andrea Ngai holds a B.S. and M.S. in Biology from San Francisco State University and brings over 15 years of experience in analytical chemistry and chromatography. She has supported both biotech and biopharma organizations, developing LC-MS methods for the characterization of complex biotherapeutics and industrial enzymes. Currently, Andrea serves as a BioPharma Technical Specialist at Agilent Technologies, where she helps customers optimize analytical and preparative workflows for large molecule therapeutics
